Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corp (NASDAQ: OPRX) provides a dedicated news hub for tracking developments in healthcare technology and digital patient engagement solutions. This page aggregates official announcements, financial disclosures, and strategic updates from the leader in EHR-integrated pharma messaging.
Investors and industry professionals will find curated coverage of earnings reports, technology partnerships, product launches, and regulatory milestones. The resource serves as a centralized source for understanding OPRX's role in connecting pharmaceutical companies with healthcare providers through cloud-based communication platforms.
Key content categories include financial results, strategic alliances with EHR providers, technology innovations in digital health messaging, and industry recognition of platform advancements. All materials maintain factual accuracy and timeliness required for informed decision-making.
Bookmark this page for streamlined access to OptimizeRx's evolving position in medication adherence solutions and AI-driven healthcare communications. Regular updates ensure stakeholders stay informed about developments impacting the digital pharma marketing landscape.
OptimizeRx Corp. (Nasdaq: OPRX) will hold a conference call on August 4, 2021, at 4:30 p.m. Eastern time to discuss its Q2 2021 results, ending June 30, 2021. Financial results will be issued ahead of the call, which will be followed by a Q&A session. The company provides digital health solutions, connecting healthcare providers and patients through its platform. This platform enhances medication adherence and creates new engagement opportunities for life science companies during the patient journey.
OptimizeRx has signed an agreement with a leading pharmaceutical company to enhance a patient affordability initiative.
The OptimizeRx platform utilizes real-world evidence (RWE) to assist physicians in managing Medicare patients’ treatment plans, preventing lapses due to coverage gaps.
This initiative aims to support patients in staying on their prescribed treatment without unexpected out-of-pocket costs, thus improving health outcomes.
OptimizeRx connects healthcare providers and patients, enhancing treatment adherence through its AI-driven platform.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, is strengthening its enterprise solutions in oncology, cardiology, and immunology. Customer engagement in these areas has surged by 600% in two years, now projected to represent at least 50% of future revenue. The company is enhancing partnerships and expanding its omni-channel platform, reaching over 50% of U.S. oncologists. Notably, specialty medicines account for 53% of spending, reflecting significant market growth.
OptimizeRx Corp. (Nasdaq: OPRX) announced that CEO Will Febbo will participate in a fireside chat at the William Blair 41st Annual Growth Stock Conference. The event will take place virtually on June 2, 2021, from 9:20-9:50 AM CT (10:20-10:50 AM ET). A live webcast and replay will be available on the company's investor relations website. OptimizeRx offers digital health solutions connecting healthcare providers and patients, aiming to enhance medication affordability and adherence.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, will participate in the RBC Capital Markets Global Healthcare Virtual Conference. CEO Will Febbo is scheduled for a fireside chat on May 19, 2021, at 8:00 a.m. ET. The presentation can be accessed live on the company's investor website. OptimizeRx offers a digital platform that connects healthcare providers and patients, enhancing medication affordability and adherence through innovative communication solutions. For updates, follow OptimizeRx on social media or visit their website.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 48% revenue increase in Q1 2021, reaching $11.2 million compared to $7.6 million year-over-year. Gross profit rose 41% to $6.1 million, though GAAP net loss was $0.6 million or $(0.04) per share.
The company achieved cash flow positivity from operations at $1.7 million, bolstered by a successful equity offering raising $70.7 million. 33 enterprise contracts worth $25 million in annual value were secured. Cash and cash equivalents soared to $82.3 million by March 31, 2021.
OptimizeRx Corporation (Nasdaq: OPRX) will hold a conference call on May 6, 2021, at 4:30 p.m. Eastern to discuss its first quarter financial results for the period ending March 31, 2021. A press release with the financial results will precede the call, where management will address questions afterward. Interested parties can access the call via a toll-free number or the web. The company is recognized for its digital health solutions, connecting a significant network of healthcare providers and patients to enhance medication adherence.
OptimizeRx Corp. (Nasdaq: OPRX) has expanded its digital health platform through new health information technology partnerships, significantly increasing its reach to over 50% of oncologists in the U.S. This initiative is aimed at enhancing connections between life science companies and healthcare providers. The partnerships diversify the channel mix available for customer engagement, which is crucial for addressing the challenges of affordability and access in oncology. The new collaborations strengthen the company’s position in delivering personalized treatment resources at the point-of-care.
FAQ
What is the current stock price of Optimizerx (OPRX)?
What is the market cap of Optimizerx (OPRX)?
